Workshop: A Design Team’s Views on Optimizing your Viral Vector for Clinical Success
24 August 2023
APPLICATIONS ARE NOW CLOSED | MEET THE PANEL
Thursday, August 24, 2023 | 11:00 [EDT] | 08:00 [PDT] | 16:00 [BST]
A VIRTUAL PARTICIPATORY WORKSHOP
Vector design and optimization is often a stumbling block for translational and clinical success.
Don’t miss this opportunity to get specific answers to your challenging questions from Dr Farzin Farzaneh, a global expert with decades of expertise and success in lentiviral and gammaretro vector design, development, and optimization. Farzin and his team have created a proprietary platform that incorporates intelligent design, helping to develop the best vector and de-risk your clinical candidate.
What would you ask Farzin and his team if you had the chance?
Audience participation is paramount at this workshop and spaces are limited. To allow us to cover as many of your questions and case studies as possible, please register your interest and provide as much detail as possible through the form below. The Phacilitate team will be in touch to let you know if your registration for this session has been successful.
Please note that the closing date for submitting questions and case studies is Monday, August 21.
Factors that impact design requirements, e.g., tumor type
Quality considerations and packaging plasmids
Overcoming titer challenges
Join us at this virtual workshop – in collaboration with the team at ViroCell Biologics – to discuss the design, development and optimization of lentiviral vectors and accelerate your pathway to the clinic.
Joining Farzin from the ViroCell Biologics team will be John Hadden, CEO & Co-Founder, Carlo Scala, Director, Process Development & Innovation and Glenda Dickson, Principal Scientist, Innovation.
MEET THE PANEL
John W. Hadden II
Chief Executive Officer & Co-Founder
Farzin Farzaneh, PhD, FRCPath, FRSB
Chief Scientific Officer & Co-Founder, ViroCell Biologics
Professor of Molecular Medicine, King’s College London
Carlo Scala, PhD
Director, Process Development & Innovation
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.